Last reviewed · How we verify
inactivated split-virus influenza vaccine
This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection.
This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection. Used for Prevention of seasonal influenza in adults and children.
At a glance
| Generic name | inactivated split-virus influenza vaccine |
|---|---|
| Sponsor | The Cleveland Clinic |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) split-virus influenza antigens that trigger both humoral and cellular immune responses. When administered, it prompts B cells to produce antibodies against viral surface proteins (hemagglutinin and neuraminidase) and activates T cells, enabling the immune system to recognize and neutralize circulating influenza viruses before they establish infection.
Approved indications
- Prevention of seasonal influenza in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children . (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: